Rouge Therapeutics secures $58 million in Series A financing co-led by Angelini Ventures and EIB to advance treatment for hereditary hemorrhagic telangiectasia.
Amount Raised
$58 Million
Round Type
Series A
RomeBiotechnologyHealth CareMedicalTherapeuticsInvestors
Description
Angelini Ventures and the European Investment Bank co-led a $58 million Series A financing in Rouge Therapeutics. The funds will support the development of RTX-001 for hereditary hemorrhagic telangiectasia, a common inherited bleeding disorder. Other participating investors included BioGeneration Ventures, Kurma Partners, and several others. This is the fourth investment made under their co-investment partnership in less than a year.
Quick answer
Rouge Therapeutics raised $58 Million in a Series A round, dated October 6, 2026. Investors: Vesalius Biocapital Partners, BioGeneration Ventures, Kurma Partners, Epidarex Capital, European Investment Bank, Angelini Ventures, ROM Utrecht Region and P53 Invest. Rouge Therapeutics is based in Rome, Lazio, Italy.
- How much did Rouge Therapeutics raise?
- Rouge Therapeutics raised $58 Million in a Series A round on October 6, 2026.
- Who invested in Rouge Therapeutics?
- Vesalius Biocapital Partners, BioGeneration Ventures, Kurma Partners, Epidarex Capital, European Investment Bank, Angelini Ventures, ROM Utrecht Region and P53 Invest are named as investors in this round.
- What does Rouge Therapeutics do?
- Rouge Tx is a spin-off from Leiden University Medical Center (LUMC) focused on developing first-in-class small-molecule therapies to restore vascular stability in diseases driven by pericyte dysfunction.
- Where is Rouge Therapeutics based and how big is it?
- Rouge Therapeutics is based in Rome, Lazio, Italy. Fundz records about 2 employees.
Source: Fundz verified event record.
Who else raised in Medical and Therapeutics around the same time
Companies in the same sectors as Rouge Therapeutics that raised within 45 days of this round, from Fundz verified event records.
- Orakl Oncology raised $34M (Series A) on November 12, 2026.
- Alethio raised $90M (Series A) on November 5, 2026.
- StimCardio raised $30M (Series A) on October 29, 2026.
- Tivic raised $85M (Series B) on October 27, 2026.
- Tivic raised $8.4M (Series B) on October 8, 2026.
- Omnio raised $3.3M (Seed) on October 2, 2026.
Who to call at Rouge Therapeutics, and when
A new round usually means Rouge Therapeutics is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Rouge Therapeutics raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Rouge Therapeutics, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Rouge Therapeutics. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Rouge Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Funding Insights
What this usually meansRouge Therapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.